ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 1606 • ACR Convergence 2022

    An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis

    nozima Aripova1, George Reed2, Bryant England1, William Robinson3, Dimitrios Pappas4, Joel Kremer5, Geoffrey Thiele1 and Ted Mikuls6, 1University of Nebraska Medical Center, Omaha, NE, 2The Corrona Research Foundation and University of Massachusetts, Albany, NY, 3Stanford University School of Medicine, Palo Alto, CA, 4CorEvitas, LLC, Waltham, MA, 5The Corrona Research Foundation, Delray Beach, FL, 6Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…
  • Abstract Number: 1685 • ACR Convergence 2022

    The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis

    Alexandra Taylor1, Michael Duryee2, Carlos Hunter2, nozima Aripova2, Ted Mikuls3 and Geoffrey Thiele2, 1Creighton University School of Medicine, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…
  • Abstract Number: 1965 • ACR Convergence 2022

    Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis

    Hsin-Yi Peng1, Ting-Yin Xue1, Fei-Hung Hsieh1, Yi-Ko Chen1, Mei-Chin Yin2, Che-Yi Chao2, Shu-Yao Tsai2, Chung-Ping Lin3, Po-Hao Huang3, Chien-Chung Huang3, Jiunn-Horng Chen3, Chung-Ming Huang3, Der-Yuan Chen4, Joung-Liang Lan5 and Gregory Tsay3, 1China Medical University, Taichung, Taiwan, 2Asia University, Taichung, Taiwan, 3China Medical University Hospital, Taichung, Taiwan, 4China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, 5China Medoical University Hospital, Taichung, Taiwan

    Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
  • Abstract Number: 1968 • ACR Convergence 2022

    Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis

    Klára Prajzlerová1, Olga Kryštůfková2, Nora Petrovská2, Petra Hánová1, Hana Hulejová1, Jiří Vencovský2, Ladislav Šenolt2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…
  • Abstract Number: 0015 • ACR Convergence 2022

    Differential Antigen Binding of Closely Related Monoclonal ACPA

    Caroline Grönwall1, Anatoly Dubnovitsky1, Philip Titcombe2, Daniel Mueller2 and vivianne malmström1, 1Karolinska Institutet, Stockholm, Sweden, 2University of Minnesota, Minneapolis, MN

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a hallmark of rheumatoid arthritis (RA) and the clonality and antigen targets of ACPA positive B cells can be…
  • Abstract Number: 2180 • ACR Convergence 2022

    Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner

    Akilan Krishnamurthy1, Jitong Sun2, Alexandra Circiumaru1, Yogan Kisten1, Koji Sakuraba3, Thuy Tran1, Peter Damberg1, Patrik Jarvoll1, Li Lu1, Katalin Sándor1, Tunhe Zhou4, vivianne malmström1, Camilla I. Svensson1, Aase Hensvold1, Anca Catrina1, Lars Klareskog1 and Bence Réthi1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Solna, Sweden, 3Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, 4Stockholm University, Stockholm, Sweden

    Background/Purpose: The appearance of anti-citrullinated protein antibodies (ACPAs) in the circulation represents a major risk factor for developing rheumatoid arthritis (RA). Here we studied whether…
  • Abstract Number: 0045 • ACR Convergence 2022

    Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)

    Alejandro Gomez1, Camille Brewer1, Jae-Seung Moon2, Suman Acharya1, Tobias V. Lanz1, Qian Wang1, Gundula Min-Oo3, Anita Niedziela-Majka3 and William Robinson4, 1Stanford University, Stanford, CA, 2Stanford University, Palo Alto, CA, 3Gilead Sciences, Foster City, CA, 4Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: ACPAs are present in two-thirds of patients with rheumatoid arthritis (RA) and are associated with higher risks for severe bone erosions. The pathogenic role…
  • Abstract Number: 0256 • ACR Convergence 2022

    Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires

    Kevin Cunningham1, Benjamin Hur2, John Davis2 and Jaeyun Sung2, 1University of Minnesota, Rochester, MN, 2Mayo Clinic, Rochester, MN

    Background/Purpose: RA is commonly diagnosed through a serological test for the presence of ACPA, and RA patients who test positive are collectively known as 'ACPA-positive…
  • Abstract Number: 0269 • ACR Convergence 2021

    Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee2, Carlos Hunter2, Punyasha Roul2, Yangyuna Yang2, Jeremy Sokolove3, William Robinson4, Joshua Baker5, Geoffrey Thiele2, Ted Mikuls2 and Bryant England2, 1University of Nebraska Medical Center, Elkhorn, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Stanford University School of Medicine, Berwyn, PA, 4Stanford University, Stanford, CA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
  • Abstract Number: 0288 • ACR Convergence 2021

    Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies

    Gregory McDermott1, Ritu Gill2, Staci Gagne3, Suzanne Byrne3, Weixing Huang3, Lauren Prisco4, Alessandra Zaccardelli3, Lily Martin3, Nancy Shadick5, Paul Dellaripa3, Tracy Doyle6 and Jeffrey Sparks3, 1Brigham and Women's Hospital, Brookline, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Pound Ridge, MA, 5Brigham & Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, West Roxbury, MA

    Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…
  • Abstract Number: 0291 • ACR Convergence 2021

    IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality

    Scott Matson1, Candace Cephers2, Timothy Wilson3, Valerie Minarchick3, Kevin Brown4, Joshua Solomon4 and Kristen Demoruelle5, 1University of Kansas, Kansas City, MO, 2St Joseph Hospital, Internal Medicine, Denver, CO, 3University of Colorado, Denver, CO, 4National Jewish Health, Denver, CO, 5University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) that shares many clinical features with rheumatoid arthritis (RA) associated ILD. Our…
  • Abstract Number: 0440 • ACR Convergence 2021

    Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events

    Kristen Mathias1, Marco Lopez Velazquez1 and Pankti Reid2, 1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Chicago, IL

    Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
  • Abstract Number: 0461 • ACR Convergence 2021

    Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria

    Meagan Chriswell1, Jennifer Seifert2, Michelle Bloom3, Cliff Rims4, Marie Feser5, Kevin Deane6, Jill Norris7, Eddie James8, Jane Buckner9, William Robinson10, V. Michael Holers11 and Kristine Kuhn12, 1UC Denver SOM, Denver, CO, 2University of Colorado School of Medicine, Littleton, CO, 3Stanford University, Redwood City, CA, 4Benaroya Research Institute, Seattle, WA, 5University of Colorado Denver, Aurora, CO, 6University of Colorado Denver, Denver, CO, 7Colorado School of Public Health, Aurora, CO, 8Benaroya Research Institute at Virginia Mason, Monroe, WA, 9Benaroya Research Institute at Virginia Mason, Seattle, WA, 10Stanford University, Palo Alto, CA, 11University of Colorado, Denver, CO, 12University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
  • Abstract Number: 0790 • ACR Convergence 2021

    Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution

    Marloes Verstappen1, Hanna van Steenbergen2, Pascal de Jong3 and Annette H.M van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden Univeristy Medical Center, Leiden, Netherlands, 3Erasmus MC, Hendrik Ido Ambacht, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…
  • Abstract Number: 0007 • ACR Convergence 2021

    Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes

    Aisha Mergaert1, Zihao Zheng1, Michael Denny1, Maya Amjadi1, Janna Bashar1, Michael Newton1, Vivianne Malmström2, Caroline Grönwall2, Sara McCoy1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti-modified protein antibodies (AMPAs), multi-reactive autoantibodies that commonly bind…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology